NEJM: Data on the endemic areas of the new coronavirus mutation, Pfizer/BioNTech vaccine demonstrates protection capabilities

▎ WuXi AppTec content team editor With the continuous emergence of new coronavirus mutant strains and the widespread epidemic in many countries and regions in the world, whether the currently used new crown vaccine can protect these mutant viruses has become a continuing concern.

Among the new coronavirus mutant strains listed by the World Health Organization as worthy of attention, the B.
1.
351 mutant strain originally discovered in South Africa has a strong immune escape ability.

The B.
1.
1.
7 mutant, which was originally discovered in the UK and is now widely circulating in many parts of the world, has a stronger spreading power.

So, what are the protection capabilities of existing vaccines against them? Today, the top medical journal "New England Journal of Medicine" published a real-world study from Qatar.

The results of this study showed that fourteen days after inoculation with two doses of the new crown vaccine BNT162b2 developed by Pfizer and BioNTech, the effectiveness of protection against B.
1.
1.
7 mutant infection was 89.
5%, and the effectiveness of protection against B.
1.
351 mutant infection.
It is 75.
0%.

The effectiveness of protection against severe, critical or fatal COVID-19 is 97.
4%.